<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on March 24, 2021</div>
    <div><br>
    </div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-</div>
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND
      EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Washington, D.C.
      20549</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM S-8</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">REGISTRATION
      STATEMENT</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">UNDER</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">THE SECURITIES
      ACT OF 1933</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Bionano
      Genomics, Inc.</div>
    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze67727a91b3a4aab9f53de9839ad8064" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Delaware</div>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">26-1756290</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction of</div>
            <div style="text-align: center; font-weight: bold;">incorporation or organization)</div>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(I.R.S. Employer</div>
            <div style="text-align: center; font-weight: bold;">Identification No.)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48%; vertical-align: middle;">&#160;</td>
          <td colspan="1" style="width: 4%; vertical-align: middle;">&#160;</td>
          <td style="width: 48%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
            <div style="text-align: center; font-weight: bold;">San Diego, California</div>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 48%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">92121</div>
          </td>
        </tr>
        <tr>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(Address of Principal Executive Offices)</div>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended</div>
    <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan</div>
    <div style="text-align: center; font-weight: bold;">(Full titles of the plans)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
    <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
    <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc.</div>
    <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
    <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
    <div style="text-align: center; font-weight: bold;">(858) 888-7600</div>
    <div style="text-align: center; font-weight: bold;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">Copies to:</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;"> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1e4bd1048bfd4d4caec19d4ed2dcf4ff" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">Thomas A. Coll, Esq.</div>
            <div style="text-align: center; font-weight: bold;">James C. Pennington, Esq.</div>
            <div style="text-align: center; font-weight: bold;">Cooley LLP</div>
            <div style="text-align: center; font-weight: bold;">4401 Eastgate Mall</div>
            <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
            <div style="text-align: center; font-weight: bold;">(858) 550-6000</div>
          </td>
          <td colspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 48%; vertical-align: top;">
            <div style="text-align: center; font-weight: bold;">R. Erik Holmlin, Ph.D.</div>
            <div style="text-align: center; font-weight: bold;">President and Chief Executive Officer</div>
            <div style="text-align: center; font-weight: bold;">Bionano Genomics, Inc.</div>
            <div style="text-align: center; font-weight: bold;">9540 Towne Centre Drive, Suite 100</div>
            <div style="text-align: center; font-weight: bold;">San Diego, California 92121</div>
            <div style="text-align: center; font-weight: bold;">(858) 888-7600</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z55b3e2afcbf94ac587d537f9fc5d3ab5" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 43.04%; vertical-align: top;">
            <div>Large accelerated filer</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
          <td style="width: 43.04%; vertical-align: top;">
            <div>Accelerated filer</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.04%; vertical-align: top;">
            <div>Non-accelerated filer</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 43.04%; vertical-align: top;">
            <div>Smaller reporting company</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.04%; vertical-align: top;">
            <div>Emerging growth company</div>
          </td>
          <td style="width: 6.96%; vertical-align: top;">
            <div style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</div>
          </td>
          <td style="width: 43.04%; vertical-align: top;">&#160;</td>
          <td style="width: 6.96%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act. <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd6e0e610a4c24f99bf6cbe967b453963" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="4" style="width: 46.22%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Title of Securities</div>
            <div style="text-align: center; font-weight: bold;">to be Registered</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Amount</div>
            <div style="text-align: center; font-weight: bold;">to be</div>
            <div style="text-align: center; font-weight: bold;">Registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-weight: bold;">Offering Price</div>
            <div style="text-align: center; font-weight: bold;">Per Share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-weight: bold;">Aggregate</div>
            <div style="text-align: center; font-weight: bold;">Offering Price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Amount of</div>
            <div style="text-align: center; font-weight: bold;">Registration Fee</div>
          </td>
        </tr>
        <tr>
          <td colspan="4" style="width: 46.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-indent: -10pt; margin-left: 10pt; font-weight: bold;">2018 Equity Incentive Plan, as amended</div>
            <div>Common Stock, $0.0001 par value per share</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">9,497,647<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">$8.90</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">$84,529,058.30</div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">$9,222.13</div>
          </td>
        </tr>
        <tr>
          <td colspan="4" style="width: 46.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-indent: -10pt; margin-left: 10pt; font-weight: bold;">2018 Employee Stock Purchase Plan</div>
            <div style="text-indent: -10pt; margin-left: 10pt;">Common Stock, $0.0001 par value per share</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">220,000<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">$8.90</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">$1,958,000</div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">$213.62</div>
          </td>
        </tr>
        <tr>
          <td colspan="4" style="width: 46.22%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-indent: -10pt; margin-left: 10pt; font-weight: bold;">Total</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">9,717,647</div>
          </td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 13.44%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">$86,487,058.30</div>
          </td>
          <td style="width: 13.46%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">$9,435.75</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.5%; vertical-align: top;">
            <div>(1)</div>
          </td>
          <td colspan="7" style="width: 96.5%; vertical-align: top;">
            <div>Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;), this Registration Statement shall also cover any additional shares of Common Stock (&#8220;<font style="font-weight: bold; font-style: italic;">Common Stock</font>&#8221;) of Bionano Genomics, Inc. (the &#8220;<font style="font-weight: bold; font-style: italic;">Registrant</font>&#8221;) that become issuable under the Registrant&#8217;s 2018 Equity Incentive
              Plan, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">2018 Plan</font>&#8221;) or the Registrant&#8217;s 2018 Employee Stock Purchase Plan (the &#8220;<font style="font-weight: bold; font-style: italic;">2018 ESPP</font>&#8221;) by reason of
              any stock dividend, stock split, recapitalization or other similar transaction.</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="width: 3.64%; vertical-align: top;">
            <div>(2)</div>
          </td>
          <td colspan="5" style="width: 96.36%; vertical-align: top;">
            <div>This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are
              based upon the average of the high and low sale prices of the Common Stock on March 18, 2021, as reported on the Nasdaq Capital Market.</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="width: 3.56%; vertical-align: top;">
            <div>(3)</div>
          </td>
          <td colspan="6" style="width: 96.44%; vertical-align: top;">
            <div>Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2021 pursuant to an &#8220;evergreen&#8221; provision contained in the 2018 Plan. Pursuant to such provision, on
              January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> of each year through January 1, 2028, the number of shares authorized for issuance under the 2018 Plan will be automatically increased by the lesser
              of: (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31 of the preceding calendar year; or (b) such lesser number of shares of Common Stock as the Registrant&#8217;s board of directors (the &#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221;) may designate prior to the applicable January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>.</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="width: 3.56%; vertical-align: top;">
            <div>(4)</div>
          </td>
          <td colspan="6" style="width: 96.44%; vertical-align: top;">
            <div>Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 ESPP on January 1, 2021 pursuant to an &#8220;evergreen&#8221; provision contained in the 2018 ESPP. Pursuant to such provision, on
              January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> of each year through January 1, 2028, the number of shares authorized for issuance under the 2018 ESPP will be automatically increased by a number
              equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 220,000 shares; or (c) such lesser number of shares of Common Stock as the Board may designate prior
              to the applicable January 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">INCORPORATION OF DOCUMENTS BY REFERENCE</div>
    <div><br>
    </div>
    <div>This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is
      effective.</div>
    <div><br>
    </div>
    <div>The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) on <a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702ds8.htm">August 28, 2018 (File No. 333-227073)</a>, <a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312519091060/d626460ds8.htm">March 29, 2019 (File No. 333-230589)</a>, <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120005371/nt10009730x2_s8.htm">March 11, 2020
        (File No. 333-237069)</a> and <a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_s8.htm">August 14, 2020 (File No. 333-245764)</a>. Pursuant to General Instruction E to Form S-8, this Registration Statement
      hereby incorporates by reference the contents of the Registration Statements referenced above.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">ITEM 8. EXHIBITS.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdcb4e6abe2764151bd97c926edce8b0a" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 8.17%; vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-weight: bold;">Exhibit</div>
            <div style="font-weight: bold;">Number</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 2px;">&#160;</td>
          <td style="width: 90%; vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000141169021000004/ex31-arcertificateofincorp.htm">4.1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Amended and Restated Certificate of Incorporation of the Registrant, as amended.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm">4.2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Amended and Restated Bylaws of the Registrant.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/0001411690/000119312518219135/d782664dex41.htm">4.3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Form of Common Stock Certificate of the Registrant.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="nt10022040x2_ex5-1.htm#ex5-1">5.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Opinion of Cooley LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="nt10022040x2_ex23-1.htm#ex23-1">23.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of BDO USA LLP, Independent Registered Public Accounting Firm.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="nt10022040x2_ex23-2.htm">23.2</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="nt10022040x2_ex5-1.htm#ex5-1">23.3</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of Cooley LLP. Reference is made to Exhibit 5.1.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="#tPOWER">24.1</a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Power of Attorney. Reference is made to the signature page hereto.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_ex99-1.htm">99.1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex105.htm">99.2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Plan.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.17%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div><a href="https://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702dex995.htm">99.3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></a></div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div>(1)</div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K, filed with the SEC on March 23, 2021.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div>(2)</div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on August 24, 2018.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div>(3)</div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-225970), as amended.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div>(4)</div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-245764).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.54%; vertical-align: top;">
            <div>(5)</div>
          </td>
          <td style="width: 96.46%; vertical-align: top;">
            <div>Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-227073).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
      to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 24, 2021.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z31f118fde25c406b91abbec15d4a28ff" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt; font-weight: bold;">BIONANO GENOMICS, INC.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: middle;">&#160;</td>
          <td style="width: 46%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-indent: -10pt; margin-left: 10pt;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-indent: -10pt; margin-left: 10pt;">/s/ R. Erik Holmlin, Ph.D.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 46%; vertical-align: bottom;">
            <div style="text-indent: -10pt; margin-left: 10pt;">R. Erik Holmlin, Ph.D.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top;">&#160;</td>
          <td style="width: 46%; vertical-align: bottom;">
            <div style="text-indent: -10pt; margin-left: 10pt; font-style: italic;">President and Chief Executive Officer</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="tPOWER"><!--Anchor--></a>POWER OF ATTORNEY</div>
    <div><br>
    </div>
    <div>KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or
      her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with
      the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
      purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</div>
    <div><br>
    </div>
    <div>Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z96365433e32f46079c230fa1cf0fce4f" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 50%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Title</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td style="width: 15.78%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="1" style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ R. Erik Holmlin,Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">President, Chief Executive Officer and Director</div>
            <div style="text-align: center; font-style: italic;">(Principal Executive Officer)</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">R. Erik Holmlin, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Christopher Stewart</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Chief Financial Officer</div>
            <div style="text-align: center; font-style: italic;">(Principal Financial and Accounting Officer)</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">Christopher Stewart</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ David L. Barker, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Director</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">David L. Barker, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Yvonne Linney, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Director</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">Yvonne Linney, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Albert A. Luderer, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Director</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">Albert A. Luderer, Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Hannah Mamuszka</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Director</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">Hannah Mamuszka</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Christopher Twomey</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Director</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">Christopher Twomey</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
          <td style="width: 15.78%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;">/s/ Kristiina Vuori, M.D., Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle; padding-bottom: 2px;">&#160;</td>
          <td rowspan="2" style="width: 50%; vertical-align: top;">
            <div style="text-align: center;">Director</div>
          </td>
          <td rowspan="2" style="width: 2%; vertical-align: middle;">&#160;</td>
          <td rowspan="2" style="width: 15.78%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2021</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: center;">Kristiina Vuori, M.D., Ph.D.</div>
          </td>
          <td style="width: 2%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "nt10022040x2_s8.htm", "description": "S-8", "secsgml_size_bytes": 48938}]
{"company-data": {"conformed-name": "Bionano Genomics, Inc", "cik": "0001411690", "assigned-sic": "3826", "irs-number": "261756290", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-254654", "film-number": "21768355"}, "business-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121", "phone": "(858) 888-7600"}, "mail-address": {"street1": "9540 TOWNE CENTRE DRIVE", "street2": "SUITE 100", "city": "SAN DIEGO", "state": "CA", "zip": "92121"}, "former-company": [{"former-conformed-name": "BioNano Genomics, Inc", "date-changed": "20120703"}, {"former-conformed-name": "BioNanomatrix Inc", "date-changed": "20070906"}]}
As filed with the Securities and Exchange Commission on March 24, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND
      EXCHANGE COMMISSION
Washington, D.C.
      20549
FORM S-8
REGISTRATION
      STATEMENT
UNDER
THE SECURITIES
      ACT OF 1933
Bionano
      Genomics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
26-1756290
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
9540 Towne Centre Drive, Suite 100
San Diego, California
92121
(Address of Principal Executive Offices)
(Zip Code)
Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan
(Full titles of the plans)
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Thomas A. Coll, Esq.
James C. Pennington, Esq.
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
(858) 550-6000
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
Bionano Genomics, Inc.
9540 Towne Centre Drive, Suite 100
San Diego, California 92121
(858) 888-7600
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated
      filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act.
☐
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount
to be
Registered
(1)
Proposed
Maximum
Offering Price
Per Share
(2)
Proposed
Maximum
Aggregate
Offering Price
(2)
Amount of
Registration Fee
2018 Equity Incentive Plan, as amended
Common Stock, $0.0001 par value per share
9,497,647
(3)
$8.90
$84,529,058.30
$9,222.13
2018 Employee Stock Purchase Plan
Common Stock, $0.0001 par value per share
220,000
(4)
$8.90
$1,958,000
$213.62
Total
9,717,647
$86,487,058.30
$9,435.75
(1)
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "
Securities Act
"), this Registration Statement shall also cover any additional shares of Common Stock ("
Common Stock
") of Bionano Genomics, Inc. (the "
Registrant
") that become issuable under the Registrant's 2018 Equity Incentive
              Plan, as amended (the "
2018 Plan
") or the Registrant's 2018 Employee Stock Purchase Plan (the "
2018 ESPP
") by reason of
              any stock dividend, stock split, recapitalization or other similar transaction.
(2)
This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are
              based upon the average of the high and low sale prices of the Common Stock on March 18, 2021, as reported on the Nasdaq Capital Market.
(3)
Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2021 pursuant to an "evergreen" provision contained in the 2018 Plan. Pursuant to such provision, on
              January 1
st
of each year through January 1, 2028, the number of shares authorized for issuance under the 2018 Plan will be automatically increased by the lesser
              of: (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31 of the preceding calendar year; or (b) such lesser number of shares of Common Stock as the Registrant's board of directors (the "
Board
") may designate prior to the applicable January 1
st
.
(4)
Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 ESPP on January 1, 2021 pursuant to an "evergreen" provision contained in the 2018 ESPP. Pursuant to such provision, on
              January 1
st
of each year through January 1, 2028, the number of shares authorized for issuance under the 2018 ESPP will be automatically increased by a number
              equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year; (b) 220,000 shares; or (c) such lesser number of shares of Common Stock as the Board may designate prior
              to the applicable January 1
st
.
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is
      effective.
The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and 2018 ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "
Commission
") on
August 28, 2018 (File No. 333-227073)
,
March 29, 2019 (File No. 333-230589)
,
March 11, 2020
        (File No. 333-237069)
and
August 14, 2020 (File No. 333-245764)
. Pursuant to General Instruction E to Form S-8, this Registration Statement
      hereby incorporates by reference the contents of the Registration Statements referenced above.
ITEM 8. EXHIBITS.
Exhibit
Number
Description
4.1
(1)
Amended and Restated Certificate of Incorporation of the Registrant, as amended.
4.2
(2)
Amended and Restated Bylaws of the Registrant.
4.3
(3)
Form of Common Stock Certificate of the Registrant.
5.1
Opinion of Cooley LLP.
23.1
Consent of BDO USA LLP, Independent Registered Public Accounting Firm.
23.2
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.
23.3
Consent of Cooley LLP. Reference is made to Exhibit 5.1.
24.1
Power of Attorney. Reference is made to the signature page hereto.
99.1
(4)
Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended.
99.2
(5)
Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2018 Plan.
99.3
(5)
Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan.
(1)
Incorporated by reference to the Registrant's Annual Report on Form 10-K, filed with the SEC on March 23, 2021.
(2)
Incorporated by reference to the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2018.
(3)
Incorporated by reference to the Registrant's Registration Statement on Form S-1 (File No. 333-225970), as amended.
(4)
Incorporated by reference to the Registrant's Registration Statement on Form S-8 (File No. 333-245764).
(5)
Incorporated by reference to the Registrant's Registration Statement on Form S-8 (File No. 333-227073).
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement
      to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 24, 2021.
BIONANO GENOMICS, INC.
By:
/s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints R. Erik Holmlin, Ph.D. as his or her true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or
      her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with
      the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and
      purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ R. Erik Holmlin,Ph.D.
President, Chief Executive Officer and Director
(Principal Executive Officer)
March 24, 2021
R. Erik Holmlin, Ph.D.
/s/ Christopher Stewart
Chief Financial Officer
(Principal Financial and Accounting Officer)
March 24, 2021
Christopher Stewart
/s/ David L. Barker, Ph.D.
Director
March 24, 2021
David L. Barker, Ph.D.
/s/ Yvonne Linney, Ph.D.
Director
March 24, 2021
Yvonne Linney, Ph.D.
/s/ Albert A. Luderer, Ph.D.
Director
March 24, 2021
Albert A. Luderer, Ph.D.
/s/ Hannah Mamuszka
Director
March 24, 2021
Hannah Mamuszka
/s/ Christopher Twomey
Director
March 24, 2021
Christopher Twomey
/s/ Kristiina Vuori, M.D., Ph.D.
Director
March 24, 2021
Kristiina Vuori, M.D., Ph.D.